EQ
Equillium, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+0.35%Oct 26, 2026, 12:30 UTC
Equillium dosed the first subject in Australia in its Phase 1 clinical trial of EQ504.
Source:Oct 6, 2026, 20:05 UTC
Equillium, Inc. announced a poster presentation of new preclinical data on EQ504 at the 50th Anniversary Equillium, Inc..
Source:Oct 5, 2026, 20:05 UTC
Equillium received Australian regulatory clearance to initiate a first-in-human clinical trial of EQ504, with dosing planned to begin by early November 2026.
Source: